CURE® Lung Cancer 2021 Special Issue 2

It is my hope that the cancer field continues to grow the novel therapy for not only patients with lung cancer, but well beyond. It is critical that the public be aware of how research and clinical trials are catalysts to better the outcomes of patients with cancer.

Targeted therapies offer new hope for patients with HER2-mutated non-small cell lung cancers.

Recent results may lead to more checkpoint inhibitor options and lower treatment prices, giving accessibility to more patients with lung cancer worldwide.

Twenty years after 9/11, a retired firefighter reflects on the weeks following the attacks, as well as his own diagnosis of lung cancer six years later, in a newly published book.

Looking deeper into mortality rates highlights the importance of eliminating disparities in lung cancer and expanding screening eligibility for at-risk populations.

Two new FDA approvals for patients with lung cancer and EGFR exon 20 insertion mutations have given the subset its first targeted therapies.

Studies show that quitting smoking after a lung cancer diagnosis has a huge payoff for patients. Many smoking cessation programs in cancer centers have tools to help patients quit.